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We thank Troth et al. for the opportunity to extend the discussion of our data on the 
mutagenicity of N4-hydroxycytidine (rNHC) [1]. We view our work as providing the 
proof-of-concept showing that as rNHC is phosphorylated to its active ribonucleoside 
5’-triphosphate, the ribonucleoside 5’-diphosphate intermediate that is the immediate 
precursor to the ribonucleoside 5’-triphosphate also plays the equivalent role of an 
intermediate precursor for the synthesis of 2’-deoxyribonucleoside 5’-diphosphate 
(by the activity of ribonucleotide reductase). This is the normal pathway for the 
synthesis of DNA precursors used from bacteria to humans; thus, it should not be a 
question of whether the mutagenic form of dNHC as a precursor to DNA is formed, 
but rather what the impact is. On this point we have unpublished cell-based data 
supporting conversion of rNHC to dNHC, albeit at low intracellular levels. Also, the 
near identity of rNHC to cytidine (the addition of a single oxygen atom) makes it likely 
that rNHC and cytidine undergo similar metabolism in the cell. 
Although we easily demonstrated the mutagenic potential of rNHC in a cell culture 
model, Troth et al. note their negative data using two in vivo model systems. 
Negative results must be viewed in the context of assay sensitivity. NHC 
mutagenesis will occur in dividing cells. Do the in vivo assays focus on dividing cells, 
and what is the limit of detection of new mutations when dividing cells are assessed? 
How do we scale these negative results to a human who may live for years? 
Mutagenesis is not an acute toxicity but, rather, would be revealed over a long period 
in cancer rates and germline mutations.  
Troth et al. raise several questions concerning our experimental approach. First, they 










rNHC has to be taken into the cell then metabolized to become a DNA precursor, a 
3-6 hour exposure would likely result in a negative result (it would likely fail as an
antiviral agent also). Short exposures are relevant to chemicals that derivatize DNA, 
not for metabolic precursors. Thus, it is important to think about the mechanism of 
mutagenesis when choosing a test for mutagenic potential, both in vitro and in vivo. 
We used a short term (5 day) cell toxicity/cytostatic assay. Troth et al. suggest this 
should have been a 32 day assessment. While we did not do this, we also did not 
notice a difference in growth rate in the presence of 3 µM rNHC during the multiple 
rounds of cell passage. 
Our results using a gene knockout model demonstrate the mutagenic potential for 
the host, but in our adaptation of the HPRT knockout model it is difficult to establish 
a mutation rate given that multiple rounds of cell replication and drug incorporation 
occurred. Highly accurate sequencing of DNA is likely better suited to ask this 
question. Ultimately the rate of mutagenesis in cell culture is less relevant than the 
long term consequences of exposure to a mutagen during treatment. 
Troth et al. pose several questions about solubility and purity.  No solubility or pH 
issues have been noted by visual inspection, and the concentrations chosen span 
those obtained in the blood with anti-HIV nucleoside analogs and also recently 
reported by Painter and colleagues studying blood levels of rNHC in people dosed 
with molnupiravir [2]. In addition, using these concentrations we found a dose-










precipitation during culture conditions. As to purity, it would be more relevant  to 
repeat this experiment with clinical grade material, which we would be happy to do. 
It is hard to argue that a ribonucleoside precursor to both RNA and DNA goes into 
one but not the other. Also, the known mutagenicity of hydroxylamine (which 
generates dNHC in DNA) suggests that if DNA repair could target such a small 
change in a base, it must do so in an incomplete way. This leads to the conclusion 
that treatment with molnupiravir will lead to mutations in host DNA in dividing cells. 
Using negative results to justify this risk as being unimportant is to create a blind 
spot for potential long term harm. Until a better understanding of treatment with 
molnupiravir is achieved, we would argue that its use should be limited to people 
with co-factor risks for COVID who are likely to receive the greatest benefit while 
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